

# Hepatitis Screening

**Policy Number:** CS053.W  
**Effective Date:** November 1, 2023

[Instructions for Use](#)

Table of Contents	Page
<a href="#">Application</a> .....	1
<a href="#">Coverage Rationale</a> .....	1
<a href="#">Definitions</a> .....	2
<a href="#">Applicable Codes</a> .....	3
<a href="#">Description of Services</a> .....	4
<a href="#">Clinical Evidence</a> .....	5
<a href="#">U.S. Food and Drug Administration</a> .....	7
<a href="#">References</a> .....	7
<a href="#">Policy History/Revision Information</a> .....	9
<a href="#">Instructions for Use</a> .....	9

Commercial Policy
<ul style="list-style-type: none"> <li><a href="#">Hepatitis Screening</a></li> </ul>

## Application

This Medical Policy does not apply to the states listed below; refer to the state-specific policy/guideline, if noted:

State	Policy/Guideline
Indiana	None
Kentucky	<a href="#">Hepatitis Screening (for Kentucky Only)</a>
Louisiana	<a href="#">Hepatitis Screening (for Louisiana Only)</a>
Nebraska	<a href="#">Hepatitis Screening (for Nebraska Only)</a>
New Jersey	<a href="#">Hepatitis Screening (for New Jersey Only)</a>
Ohio	<a href="#">Hepatitis Screening (for Ohio Only)</a>
Pennsylvania	<a href="#">Hepatitis Screening (for Pennsylvania Only)</a>
Tennessee	<a href="#">Hepatitis Screening (for Tennessee Only)</a>

## Coverage Rationale

**Hepatitis A** testing is proven and medically necessary for individuals who were born in or have travelled to regions with high or moderate prevalence of Hepatitis A virus (HAV).

**Hepatitis B** screening is proven and medically necessary in individuals with the following indications:

- Blood transfusion prior to 1992
- Birth in or travel to regions with high or moderate prevalence of Hepatitis B virus (HBV) infection
- Elevated ALT/AST of unknown etiology
- Clotting-factor disorders, such as hemophilia
- Exposure to blood or body fluids
- Donors of blood, plasma, organs, tissue, or semen
- Following exposure to an individual with HBV infection through household, secondary contacts or needle sharing

- Hemodialysis
- High-risk sexual behavior
- HIV-positive infection, and those who are high risk of HIV acquisition
- Immunosuppression due to immunosuppressive therapy for rheumatologic or gastroenterologic disorders, chemotherapy, and organ transplantation
- Infants born in the U.S. whose parents were born in regions with high rates of Hepatitis B
- Infants born to HBV infected mothers
- Men who have sexual relations with men (MSM)
- Pregnancy
- Present sexual partner is infected with HBV
- Prior to anti-TNF initiation
- Recipient of clotting factor concentrates made before 1987
- Recipients of blood or organs from a donor who later tested HBV positive
- Residents and institutional care workers
- Current and past recreational use of injection drug(s), including those individuals with a history limited to a single use of injection drug and regardless of the duration since use

**Hepatitis C virus (HCV) screening is proven and medically necessary in adults aged 18 to 79 years whether or not risk factors have been identified.**

## Definitions

**Hepatitis A:** A highly contagious viral condition that causes inflammation affecting the liver's ability to function. Hepatitis A virus (HAV) infection is primarily transmitted by the fecal-oral route, by either person-to-person contact or consumption of contaminated food or water. Although viremia occurs early in infection and can persist for several weeks after onset of symptoms, bloodborne transmission of HAV is uncommon. HAV, has an incubation period of approximately 28 days (range: 15-50 days). HAV replicates in the liver and is shed in high concentrations in feces from 2 weeks before to 1 week after the onset of clinical illness. HAV infection produces a self-limited disease that does not result in chronic infection or chronic liver disease (CDC, 2020).

**Hepatitis A Antibody Test:** Hepatitis A Antibody Testing, also known as Hepatitis A Total Antibody Testing, is performed to determine whether an individual is currently infected with HAV or has previously had HAV infection. Positive antibodies mean a person has HAV, has previously had HAV, or has been vaccinated against the virus. This person is immune to future HAV infection. When antibodies are undetected, the test result will indicate negative. These individuals are susceptible to HAV infection (Center for Substance Abuse Treatment, 2011).

**Hepatitis B:** Hepatitis B virus (HBV) is transmitted through exposure to infective blood, semen, and other body fluids. HBV can be transmitted from infected mothers to infants at the time of birth or from family member to infant in early childhood. Transmission may also occur through transfusions of HBV-contaminated blood and blood products, contaminated injections during medical procedures, and through injection drug use. HBV also poses a risk to healthcare workers who sustain accidental needle stick injuries while caring for infected-HBV patients. Among persons with chronic HBV infection, the risk for premature death from cirrhosis or hepatocellular carcinoma is 15% to 25% (CDC, 2020).

**Hepatitis B Core Antibody Test (anti-HBc):** At the onset of symptoms in acute Hepatitis B, the total Hepatitis B core antibody appears and persists for life. The presence of anti-HBc indicates previous or ongoing infection with Hepatitis B virus in an undefined time frame (CDC Division of Viral Hepatitis, 2005; updated 2023).

**Hepatitis B Surface Antigen Test (HBsAg):** HBsAg is a protein on the surface of the Hepatitis B virus. During acute or chronic HBV infection, HBsAg can be detected in high levels in serum. As part of the normal immune response to infection, the body normally produces antibodies to HBsAg; however, the presence of HBsAg indicates that the person is infectious (CDC Division of Viral Hepatitis, 2005; updated 2023).

**Hepatitis B Surface Antibody Test (anti-HBs):** The presence of anti-HBs is interpreted as recovery and immunity from Hepatitis B virus infection. Anti-HBs also develops in a person who has been successfully vaccinated against Hepatitis B.

Among vaccine recipients who have completed a series, anti-HBs levels may decline over time, however the majority are still immune and will mount a response when exposed to HBV (CDC Division of Viral Hepatitis, 2005; updated 2023).

**Hepatitis C:** Hepatitis C virus (HCV) is mostly transmitted through direct percutaneous exposure to blood. This may happen through transfusions of HCV-contaminated blood and blood products, contaminated injections during medical procedures, and through injection drug use. Sexual transmission is also possible but is much less common. According to the Center for Disease Prevention and Control and Prevention (CDC) Hepatitis C Guideline, Hepatitis C virus (HCV), is the most common chronic bloodborne pathogen in the United States; approximately 2.7-3.9 million persons are chronically infected (CDC, 2020).

**Hepatitis C Antibody Test (anti-HCV):** The HCV Antibody Test, also known as an anti-HCV test, looks for antibodies to the Hepatitis C virus in the blood. A negative or non-reactive test result means the patient is not currently infected. However, if there has been exposure to HCV within the last six months, repeat testing will need to be performed. A positive or reactive test means you have been infected with the Hepatitis C virus at some point in time. Once infected, the patient will always have antibodies in their blood. This is true whether they have cleared the virus, have been cured, or still have the virus in their blood. A reactive antibody test does not necessarily mean the patient currently has Hepatitis C, and a follow-up test will be required (CDC Division of Viral Hepatitis, 2020).

**Hepatitis D:** Hepatitis D (HDV), also known as "delta hepatitis," is a serious liver disease caused by infection with the Hepatitis D virus. This is an RNA virus structurally unrelated to the Hepatitis A, B, or C viruses. Hepatitis D, which can be acute or chronic, is uncommon in the United States. HDV is an incomplete virus that requires the helper function of HBV to replicate and only occurs among people who are infected with the Hepatitis B virus (HBV). The dual infection of HDV and HBV can result in a more serious disease and worse outcome (CDC, 2020).

**Hepatitis E:** The Hepatitis E virus (HEV) is spread by the fecal-oral route; however, in developing countries where HEV genotypes 1 and 2 are predominant, HEV infection through contaminated drinking water is the most common source. In addition, certain mammals can become infected with HEV and consumption of raw or undercooked meat or organs from infected animals can lead to foodborne HEV transmission to humans. HEV RNA (genotypes 3 and 4) has been extracted from deer, boar and pork meat. HEV infection should be considered in any person with symptoms of viral hepatitis who tests negative for serologic markers of Hepatitis A, Hepatitis B, Hepatitis C, other hepatotropic viruses, and all other causes of acute liver injury (CDC Division of Viral Hepatitis, 2020).

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
86704	Hepatitis B core antibody (HBcAb); total
86705	Hepatitis B core antibody (HBcAb); IgM antibody
86706	Hepatitis B surface antibody (HBsAb)
86707	Hepatitis Be antibody (HBeAb)
86708	Hepatitis A antibody (HAAb)
86709	Hepatitis A antibody (HAAb); IgM antibody
86803	Hepatitis C antibody
86804	Hepatitis C antibody; confirmatory test (e.g., immunoblot)
87340	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; hepatitis B surface antigen (HBsAg)

CPT Code	Description
87341	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; hepatitis B surface antigen (HBsAg) neutralization
87350	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; hepatitis Be antigen (HBeAg)
87467	Infectious agent antigen detection by immunoassay technique (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; Hepatitis B surface antigen (HBsAg), quantitative
87902	Infectious agent genotype analysis by nucleic acid (DNA or RNA); hepatitis C virus
87912	Infectious agent genotype analysis by nucleic acid (DNA or RNA); hepatitis B virus

*CPT® is a registered trademark of the American Medical Association*

HCPCS Code	Description
G0472	Hepatitis C antibody screening for individual at high risk and other covered indication(s)
G0499	Hepatitis B screening in non-pregnant, high-risk individual includes hepatitis B surface antigen (HBSAG), antibodies to HBSAG (anti-HBS) and antibodies to hepatitis B core antigen (anti-HBC), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive HBSAG result

#### Diagnosis Codes

[Hepatitis Screening: Diagnosis Code List](#)

## Description of Services

The word “hepatitis” means inflammation of the liver. Viral hepatitis is caused by infection with any of at least five distinct viruses: (A, B, C, D, and E). The most common types are Hepatitis A, Hepatitis B, and Hepatitis C. All the major hepatotropic viruses can cause viral hepatitis but only Hepatitis B with or without co-infection with Hepatitis D and Hepatitis C can cause liver disease. Chronic infection can lead to cirrhosis and hepatocellular carcinoma (CDC Division of Viral Hepatitis, 2020).

In the United States, new cases of Hepatitis B virus (HBV) among adults are largely transmitted through injection drug use or sexual intercourse, but most prevalent cases of HBV infection are chronic infections from exposure occurring in infancy or childhood. Another major risk factor for HBV infection is country of origin. In the United States, adults with HBV born in high-prevalence countries were commonly infected during childhood. In children, the primary source of infection is perinatal transmission at birth.

Testing and diagnosis of Hepatitis B and C infection is the gateway for access to both prevention and treatment services and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and Hepatitis B vaccination. (WHO, 2017).

The USPSTF maintains a list of countries and their estimated prevalence of HCV. Complete information can be found at: <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-b-virus-infection-screening#bootstrap-panel-6>. (Accessed June 21, 2023).

## Transmission and Clinical Course of Viral Hepatitis (CDC, 2020)

Hepatitis Virus	Transmission Route	Incubation Period	Likelihood of Chronic Disease	Treatment
HAV	<ul style="list-style-type: none"> <li>Fecal-oral</li> <li>Close person-to-person contact with an infected person</li> <li>Sexual contact</li> <li>Ingestion of contaminated food or water</li> </ul>	15-50 days (average: 28 days)	None	<ul style="list-style-type: none"> <li>No medication available</li> <li>Best addressed through supportive treatment</li> </ul>
HBV	<ul style="list-style-type: none"> <li>Percutaneous, mucosal, or nonintact skin exposure to infectious blood, semen, and other body fluids. HBV is concentrated most highly in blood, and percutaneous exposure is an efficient mode of transfer</li> </ul>	60-150 days (average: 90 days)	Chronic infection develops in: <ul style="list-style-type: none"> <li>90% of infants after acute infection at birth</li> <li>25%-50% of children newly infected at ages 1-5 years</li> <li>5% of people newly infected as adults</li> </ul>	<ul style="list-style-type: none"> <li>Acute: no medication available; best addressed through supportive treatment</li> <li>Chronic: regular monitoring for signs of liver disease progression; antiviral drugs are available</li> </ul>
HCV	<ul style="list-style-type: none"> <li>Direct percutaneous exposure to infectious blood. Mucous membrane exposures to blood can also result in transmission, although this route is less efficient</li> </ul>	14-182 days (average range: 14-84 days)	Chronic infection develops in over 50% of newly infected people	<ul style="list-style-type: none"> <li>Acute: AASLD/IDSA recommend treatment of acute HCV without a waiting period</li> <li>Chronic: over 90% of people with HCV can be cured regardless of HCV genotype with 8-12 weeks of oral therapy</li> </ul>

## Clinical Evidence

Pauly et al. (2018) conducted a retrospective analysis of 8,887 adult patients. They each began treatment with TNF antagonists for autoimmune diseases (dermatologic, rheumatologic, or gastrointestinal) from 2001 through 2010, followed through December 2012. The authors obtained data on HBV infection (52% of patients were screened for HBV before treatment), demographic features, comorbidities, and use of immunosuppressive agents. Of the 4,267 patients with unknown HBV status at baseline, 2 had HBV reactivation. Those treated with TNF antagonists for autoimmune diseases, had 39% HBV reactivation rate in those who were HBsAg+ before therapy, but not patients who were HBsAg-negative and anti-HBc+ before therapy. The authors concluded that patients should be screened for HBV infection before anti-TNF therapy; HBsAg+ patients should receive prophylactic antiviral therapy, but not HBsAg-negative, anti-HBc+ patients.

### Clinical Practice Guidelines

#### *American College of Obstetricians and Gynecologists (ACOG)*

In May 2021, reaffirmed January 2022, the American College of Obstetricians and Gynecologists (ACOG) Practice Advisory recommended hepatitis C screening for all pregnant individuals during each pregnancy. Screening during the first prenatal blood assessment obtained in every pregnancy is recommended to identify pregnant individuals with HCV infection and infants who should receive testing at a pediatric visit.

A 2007 practice bulletin, reaffirmed in 2021, states that routine prenatal screening of all pregnant women by hepatitis B surface antigen (HBsAg) testing is recommended.

## ***American Association for the Study of Liver Disease (AASLD)***

In a practice guideline published by Terrault et al. (2018) for the prevention, diagnosis, and treatment of chronic hepatitis B, the American Association for the Study of Liver Disease (AASLD) recommends screening for the following persons:

- All persons born in countries with a HBsAg seroprevalence of 2%
- U.S. born persons not vaccinated as infants whose parents were born in regions with high HBV endemicity (8%)
- Pregnant women
- Persons needing immunosuppressive therapy
- Persons who have ever injected drugs
- Men who have sex with men
- Individuals with elevated ALT or AST of unknown etiology
- Donors of blood, plasma, organs, tissues, or semen
- Persons with end-stage renal disease, including pre-dialysis, hemodialysis, peritoneal dialysis, and home dialysis patients
- Infants born to HBsAg-positive mothers
- Persons with chronic liver disease
- Persons with HIV
- Household, needle-sharing, and sexual contacts of HBsAg-positive persons
- Persons who are not in a long-term, mutually monogamous relationship (e.g., > 1 sex partner during the previous 6 months)
- Persons seeking evaluation or treatment for a sexually transmitted disease
- Health care and public safety workers at risk for occupational exposure to blood or blood-contaminated body fluids
- Residents and staff of facilities for developmentally disabled persons
- Travelers to countries with intermediate or high prevalence of HBV infection
- Persons who are the source of blood or body fluid exposures that might require postexposure prophylaxis
- Inmates of correctional facilities
- Unvaccinated persons with diabetes who are aged 19 through 59 years

In 2019, the AASLD and the Infectious Diseases Society of America (IDSA), revised their guidance on the identification and management of chronic hepatitis C (HCV). The guidance includes a new recommendation that all adults be screened for HCV. In addition to universal screening for hepatitis C, the guidance emphasizes universal treatment.

## ***American Gastroenterological Association (AGA)***

The American Gastroenterological Association (AGA) guideline titled prevention and treatment of hepatitis B virus reactivation (HBVr) during immunosuppressive drug therapy, recommends screening for HBV (HBsAg and anti-HBc, followed by a sensitive HBV DNA test if positive) in patients at moderate or high risk who will undergo immunosuppressive drug therapy. The AGA recommended against routinely screening for HBV in patients who will undergo immunosuppressive drug therapy and are at low risk (Reddy et al, 2014, retired – update in progress).

## ***Centers for Disease Control and Prevention (CDC)***

Schillie et al. (2020) presented the CDC recommendations for Hepatitis C screening for adults, from the Morbidity and Mortality Weekly Report (MMWR). The CDC recommends hepatitis C screening of all adults aged  $\geq 18$  years once in their lifetime, and screening of all pregnant women (regardless of age) during each pregnancy. The recommendations include an exception for settings where the prevalence of HCV infection is demonstrated to be  $< 0.1\%$ ; however, few settings are known to exist with a hepatitis C prevalence below this threshold. The recommendation for testing of persons with risk factors remains unchanged from 2017; those with ongoing risk factors should be tested regardless of age or setting prevalence, including continued periodic testing if risks persist.

## ***North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN)***

The 2012 NASPGHAN's practice guidelines on diagnosis and management of hepatitis C infection in infants, children, and adolescents state the following individuals should be screened for HCV infection:

- Persons with recent or past use of drug injections (even those who only injected once and do not consider themselves drug users)
- Persons with conditions known to have a high incidence of Hepatitis C such as HIV infection, history of hemodialysis and unexplained abnormal aminotransferase levels
- Recipients of blood transfusions, blood products, or organ transplants before July 1992



- Children born to HCV infected mothers
- Following needle-stick injuries
- Present sexual partners of HCV infected individuals
- Children with chronically elevated transaminases
- Children from a region with high prevalence of HCV infection

### ***U.S. Preventive Services Task Force (USPSTF)***

In 2020, to update its 2014 recommendation, the U.S. Preventive Services Task Force (USPSTF) commissioned a review of new randomized clinical trials and cohort studies published from 2014 to August 2019, that evaluated the benefits and harms of screening and antiviral therapy for preventing intermediate outcomes or health outcomes and the association between improvements in intermediate outcomes and health outcomes. New key questions focused on the yield of alternative HBV screening strategies and the accuracy of tools to identify persons at increased risk. This recommendation statement applies to asymptomatic, nonpregnant adolescents and adults at increased risk for HBV infection, including those who were vaccinated before being screened for HBV infection. The draft recommendation is consistent with the 2014 recommendation. It is strengthened by new evidence from trials and cohort studies reporting that antiviral therapy reduces risk of mortality and hepatocellular carcinoma and improves intermediate outcomes that are consistently associated with better health outcomes. The USPSTF concludes with moderate certainty that screening for HBV infection in adolescents and adults at increased risk for infection has moderate net benefit, and therefore recommends screening for HBV infection in adolescents and adults at increased risk for infection (B recommendation).

In 2020, the USPSTF updated its recommendation for screening for HCV infection to apply to all adults aged 18 to 79 years. In its Practice Considerations section of the updated recommendation, the USPSTF also clarifies that clinicians may want to consider screening in adolescents younger than 18 years and in adults older than 79 years who are at high risk (e.g., past or current injection drug use). It also concludes that because of the increasing prevalence of HCV infection in women aged 15 to 44 years and in infants born to HCV infected mothers, clinicians may want to consider screening pregnant person younger than 18 years. The USPSTF concluded that broadening the age for HCV screening beyond its previous recommendation will identify infected patients at earlier stages of disease who could greatly benefit from effective treatment before developing complications.

In 2019, the USPSTF reaffirmed its 2009 recommendation that the benefits outweigh the harms and screening for hepatitis B virus (HBV) is recommended for women at their first prenatal visit to reduce perinatal transmission and the development of chronic HBV infection. Vaccination of all infants against HBV infection and providing postexposure prophylaxis with hepatitis B immune globulin (HBIG) at birth to infants of mothers infected with HBV substantially reduce the risk for acquisition of HBV infection in infants.

## **U.S. Food and Drug Administration (FDA)**

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Laboratories that perform hepatitis antibody screening are regulated by the FDA under the Clinical Laboratory Improvement Amendments. Refer to the following website for more information:

<http://www.fda.gov/medicaldevices/deviceregulationandguidance/ivdregulatoryassistance/ucm124105.htm>.

(Accessed June 21, 2023)

## **References**

American Academy of Pediatrics. 2021-2024 Report of the Committee on Infectious Diseases. Section 3: summaries of infectious diseases. Hepatitis B. Serologic testing; p.390. Available at: <https://publications.aap.org/redbook/book/347/Red-Book-2021-2024-Report-of-the-Committee-on?autologincheck=redirected>. Accessed June 21, 2023.

American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2019, Dec 3. Available at: <https://www.hcvguidelines.org/>. Accessed June 21, 2023.

American College of Obstetricians and Gynecologists (ACOG) Practice Advisory. Routine hepatitis C screening in pregnant individuals. May 2021; Reaffirmed January 2022. Available at: <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/05/routine-hepatitis-c-virus-screening-in-pregnant-individuals>. Accessed June 21, 2023.

American College of Obstetricians and Gynecologists (ACOG). Practice bulletin no. 86: viral hepatitis in pregnancy. October 2007; Reaffirmed January 2012. Available at: <https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2007/10/viral-hepatitis-in-pregnancy>. Accessed June 21, 2023.

Brunasso AM, Puntoni M, Gulia A, et al. Safety of anti-tumor necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. *Rheumatology (Oxford)*. 2011 Sep;50(9):1700-11.

Center for Substance Abuse Treatment. Addressing viral hepatitis in people with substance use disorders. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2011. (Treatment Improvement Protocol (TIP) Series, No. 53.) 2, Screening for Viral Hepatitis. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK92029/>. Accessed June 21, 2023.

Centers for Disease Control and Prevention (CDC). CDC recommendations for hepatitis screening among adults – United States, 2020. Division of Viral Hepatitis. Atlanta, GA. 2020.

Centers for Disease Control and Prevention (CDC) Division of Viral Hepatitis. Interpretation of hepatitis B serologic test results. 2005; updated 2011. <https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm>. Accessed June 21, 2023.

Centers for Disease Control and Prevention (CDC) Division of Viral Hepatitis. Atlanta, GA. 2017.

Chou R, Dana T, Bougatsos C, et al. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force Recommendation. *Ann Intern Med*. 2015.

Henderson JT, Webber EM, Bean SI. Screening for hepatitis B virus infection in pregnant women: an updated systematic review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Jul. Report No.: 19-05248-EF-1.

Karadeniz A, Akduman Alaşehir E. Seroepidemiology of hepatitis viruses, measles, mumps, rubella and varicella among healthcare workers and students: should we screen before vaccination? *J Infect Public Health*. 2020 Apr;13(4):480-484.

Mack CL, Gonzalez-Peralta RP, Gupta N; North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. *J Pediatr Gastroenterol Nutr*. 2012 Jun;54(6):838-55.

Pauly et al. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. *Clin Gastroenterol Hepatol*. 2018 Dec;16(12):1964-1973.e1.

Quest Diagnostics TM. Viral hepatitis: laboratory support of diagnosis and management. 2017. Updated 2021.

Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. *Gastroenterology*. 2014;148(1):215-219.

Schillie et al. CDC recommendations for hepatitis C screening among adults – United States, 2020. *Morbidity and Mortality Weekly Report (MMWR) Recomm Rep*, 2020.

Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018 Apr;67(4):1560-1599.

U.S. Preventive Services Task Force (USPSTF). Screening for hepatitis B virus infection in adolescents and adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2020 Dec 15;324(23):2415-2422.

U.S. Preventive Services Task Force (USPSTF). Hepatitis C virus infection in adolescents and adults. Screening: Rockville, MD: March 2020.

U.S. Preventive Services Task Force (USPSTF). Screening for hepatitis B virus infection in pregnant women. Rockville, MD: Reaffirmed 2019.

van Rooijen M, Heijman T, de Vrieze N, et al. Earlier detection of hepatitis C virus infection through routine hepatitis C virus antibody screening of human immunodeficiency virus-positive men who have sex with men attending a sexually transmitted infection outpatient clinic: a longitudinal study. *Sex Transm Dis*. 2016;43(9):560-565.

World Health Organization. Guidelines on hepatitis B and C testing. Geneva. February 2017.



## Policy History/Revision Information

Date	Summary of Changes
11/01/2023	<p data-bbox="337 216 480 247"><b>Definitions</b></p> <ul data-bbox="337 254 1125 285" style="list-style-type: none"><li data-bbox="337 254 1125 285">• Added definition of “Hepatitis B Surface Antibody Test (anti-HBs)”</li></ul> <p data-bbox="337 291 643 323"><b>Supporting Information</b></p> <ul data-bbox="337 329 1138 388" style="list-style-type: none"><li data-bbox="337 329 1138 361">• Updated <i>References</i> section to reflect the most current information</li><li data-bbox="337 367 854 388">• Archived previous policy version CS053.V</li></ul>

## Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state, or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state, or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state, or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state, or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual<sup>®</sup> criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.